


PREVALENCE of cancer of the PANCREAS in SWITZERLAND

Figure 1. Observed and projected number of patients having been diagnosed with malignant cancer of the pancreas by index year and years since diagnosis.



**Table 1. Malignant cancer of the pancreas (ICD-10 C25).
Limited-duration prevalence in Switzerland by sex, age and year.**

		Limited-duration prevalence ²															
		Men								Women							
		2000		2005		2010		2015		2000		2005		2010		2015	
Age ³	Time since diagnosis [years]	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹	N	Prop ¹
0-49	up to 2	16	0.7	21	0.8	32	1.3	35	1.4	18	0.8	23	1.0	24	1.0	26	1.0
	up to 5	20	0.8	29	1.2	40	1.6	45	1.7	20	0.8	37	1.5	35	1.4	34	1.4
	up to 10	24	1.0	31	1.3	43	1.7	49	1.9	22	0.9	37	1.5	50	2.0	44	1.8
	2 to 5	4	0.2	8	0.3	8	0.3	10	0.4	2	0.1	14	0.6	11	0.4	8	0.3
	5 to 10	4	0.2	2	0.1	3	0.1	4	0.2	2	0.1	0	0.0	15	0.6	10	0.4
50-59	up to 2	57	12.1	57	11.6	48	9.1	55	9.1	43	9.3	45	9.3	43	8.1	57	9.7
	up to 5	70	15.0	61	12.5	63	11.8	75	12.4	62	13.2	64	13.2	61	11.6	78	13.2
	up to 10	82	17.5	66	13.6	74	13.9	85	14.1	62	13.2	82	16.8	71	13.5	86	14.6
	2 to 5	14	2.9	4	0.9	14	2.7	20	3.3	19	4.0	19	3.9	18	3.5	20	3.5
	5 to 10	11	2.4	5	1.1	11	2.1	10	1.7	0	0.0	18	3.6	10	1.8	8	1.4
60-69	up to 2	83	26.4	85	23.4	173	41.2	183	41.1	95	27.1	111	28.6	124	28.3	143	31.0
	up to 5	108	34.3	97	26.9	206	49.2	214	48.1	109	30.9	137	35.4	153	35.0	178	38.8
	up to 10	115	36.3	113	31.2	209	49.9	225	50.5	115	32.7	142	36.7	170	38.7	191	41.6
	2 to 5	25	7.9	13	3.5	33	7.9	31	7.0	13	3.8	26	6.8	30	6.7	36	7.8
	5 to 10	6	2.0	16	4.3	3	0.7	10	2.4	6	1.8	5	1.3	16	3.7	13	2.8
70-79	up to 2	92	43.6	107	47.0	120	48.0	134	45.9	81	27.8	130	43.4	106	34.2	148	43.3
	up to 5	97	46.1	129	56.7	152	60.7	177	60.4	104	35.4	154	51.1	150	48.3	199	57.9
	up to 10	112	53.2	149	65.3	169	67.4	198	67.6	104	35.4	169	56.3	185	59.6	234	68.2
	2 to 5	5	2.5	22	9.6	32	12.6	43	14.5	22	7.6	23	7.7	44	14.1	50	14.7
	5 to 10	15	7.1	20	8.7	17	6.7	21	7.2	0	0.0	16	5.2	35	11.3	35	10.2
80+	up to 2	42	44.1	55	48.4	53	40.5	71	46.9	55	27.9	123	55.0	96	39.1	116	44.0
	up to 5	52	54.3	63	56.0	61	46.1	87	57.4	64	32.1	144	64.7	113	46.0	132	50.1
	up to 10	56	57.8	66	57.9	76	57.5	99	65.3	66	33.2	156	70.0	140	56.9	162	61.6
	2 to 5	10	10.2	9	7.7	7	5.7	16	10.5	8	4.2	22	9.7	17	6.9	16	6.1
	5 to 10	3	3.5	2	1.9	15	11.4	12	8.0	2	1.1	12	5.3	27	10.9	30	11.5
All ages	up to 2	290	8.2	324	8.9	427	11.0	478	11.7	293	8.0	432	11.4	393	9.8	490	11.8
	up to 5	348	9.9	381	10.4	522	13.5	598	14.7	358	9.7	537	14.1	512	12.8	621	14.9
	up to 10	388	11.0	426	11.7	570	14.7	656	16.1	368	10.0	587	15.4	615	15.4	717	17.2
	2 to 5	58	1.7	56	1.5	95	2.5	120	2.9	65	1.8	104	2.7	119	3.0	131	3.1
	5 to 10	40	1.1	45	1.2	49	1.3	58	1.4	10	0.3	50	1.3	103	2.6	96	2.3

¹ Proportion per 100'000

² Estimated with Counting/Projection-Method (see chapter B and C in document "Prevalence estimation methods")

³ Age at index date

[Complete prevalence not estimated (see "Prevalence estimation methods", chapter D.4.)]

May 2014

Contact: Matthias Lorez, PhD MAS
Foundation National Institute for Cancer Epidemiology and Registration (NICER)
c/o Universität Zürich
Seilergraben 49
CH-8001 Zürich
ml@nicer.org